These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 24219400)

  • 1. Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects.
    Neelakantan P; Rezvani K; May P; Gerrard G; Marco B; Paliompeis C; Reid A; Goldman J; Marin D; Milojkovic D
    Br J Haematol; 2014 Feb; 164(4):608-10. PubMed ID: 24219400
    [No Abstract]   [Full Text] [Related]  

  • 2. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
    Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
    J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.
    Hehlmann R; Müller MC; Lauseker M; Hanfstein B; Fabarius A; Schreiber A; Proetel U; Pletsch N; Pfirrmann M; Haferlach C; Schnittger S; Einsele H; Dengler J; Falge C; Kanz L; Neubauer A; Kneba M; Stegelmann F; Pfreundschuh M; Waller CF; Spiekermann K; Baerlocher GM; Ehninger G; Heim D; Heimpel H; Nerl C; Krause SW; Hossfeld DK; Kolb HJ; Hasford J; Saußele S; Hochhaus A
    J Clin Oncol; 2014 Feb; 32(5):415-23. PubMed ID: 24297946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chronic myeloid leukemia: up-to-date management].
    Nakayama K; Inokuchi K
    Rinsho Ketsueki; 2014 Jan; 55(1):42-55. PubMed ID: 24492036
    [No Abstract]   [Full Text] [Related]  

  • 5. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation.
    Hussein K; Bock O; Seegers A; Flasshove M; Henneke F; Buesche G; Kreipe HH
    Blood; 2007 May; 109(9):4106-7. PubMed ID: 17449802
    [No Abstract]   [Full Text] [Related]  

  • 6. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib.
    Hughes TP; Lipton JH; Spector N; Cervantes F; Pasquini R; Clementino NC; Dorlhiac Llacer PE; Schwarer AP; Mahon FX; Rea D; Branford S; Purkayastha D; Collins L; Szczudlo T; Leber B
    Blood; 2014 Jul; 124(5):729-36. PubMed ID: 24948656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia.
    Machaczka M; Gossart M
    Pol Arch Med Wewn; 2013; 123(5):251-2. PubMed ID: 23722191
    [No Abstract]   [Full Text] [Related]  

  • 8. [Management of chronic myeloid leukemia].
    Kubuki Y
    Rinsho Ketsueki; 2008 Oct; 49(10):1401-10. PubMed ID: 18833925
    [No Abstract]   [Full Text] [Related]  

  • 9. Skin and oral lesions associated to imatinib mesylate therapy.
    Basso FG; Boer CC; Corrêa ME; Torrezan M; Cintra ML; de Magalhães MH; da Silva Santos P; de Souza CA
    Support Care Cancer; 2009 Apr; 17(4):465-8. PubMed ID: 19037666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib-induced postoperative periorbital purpura: GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia.
    Anzalone CL; Cohen PR; Kurzrock R; Cortes JE
    Dermatol Online J; 2014 Jan; 20(1):21242. PubMed ID: 24456946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient with chronic myeloid leukemia in complete cytogenetic response: what does it mean, and what does one do next?
    Marin D
    J Clin Oncol; 2014 Feb; 32(5):379-84. PubMed ID: 24419129
    [No Abstract]   [Full Text] [Related]  

  • 12. Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy.
    Gambacorti-Passerini C; Piazza R
    Am J Hematol; 2011 Jul; 86(7):531-2. PubMed ID: 21674581
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up.
    Gallipoli P; Stobo J; Heaney N; Nicolini FE; Clark R; Wilson G; Tighe J; McLintock L; Hughes T; Michor F; Paul J; Drummond M; Holyoake TL
    Br J Haematol; 2013 Dec; 163(5):674-6. PubMed ID: 24032404
    [No Abstract]   [Full Text] [Related]  

  • 14. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
    Hochhaus A
    Expert Opin Pharmacother; 2007 Dec; 8(18):3257-64. PubMed ID: 18035968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.
    Kalmanti L; Saussele S; Lauseker M; Müller MC; Dietz CT; Heinrich L; Hanfstein B; Proetel U; Fabarius A; Krause SW; Rinaldetti S; Dengler J; Falge C; Oppliger-Leibundgut E; Burchert A; Neubauer A; Kanz L; Stegelmann F; Pfreundschuh M; Spiekermann K; Scheid C; Pfirrmann M; Hochhaus A; Hasford J; Hehlmann R
    Leukemia; 2015 May; 29(5):1123-32. PubMed ID: 25676422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when is this a safe option to consider?
    Sweet K; Oehler V
    Hematology Am Soc Hematol Educ Program; 2013; 2013():184-8. PubMed ID: 24319180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical progress in chronic myelogenous leukemia].
    Matsunaga T
    Rinsho Ketsueki; 2009 Oct; 50(10):1489-99. PubMed ID: 19915358
    [No Abstract]   [Full Text] [Related]  

  • 18. [Intestinal bleeding in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors].
    Saito M; Izumiyama K; Mori A; Irie T; Tanaka M; Morioka M; Saga A; Musashi M; Kato T; Meguro T; Tanino M
    Rinsho Ketsueki; 2014 Jan; 55(1):130-2. PubMed ID: 24492046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial treatment for patients with CML.
    Goldman JM
    Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.